This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): UltiMab, CNTO 148, golimumab SQ
Description: BioMedTracker has separate drug profiles for the SQ and IV formulations of Simponi. Please also see Simponi (IV).
SIMPONI (golimumab) is a human monoclonal antibody specific for human tumor necrosis factor alpha (TNF-alpha). Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFa. This interaction prevents the binding of TNFa to its receptors, thereby inhibiting the biological activity of TNFa (a cytokine protein). There was no evidence of the golimumab antibody binding to other TNF superfamily ligands; in particular, the golimumab antibody did not bind or neutralize human lymphotoxin. Golimumab did not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Centocor and Medarex
In 2002, Centocor reported that it was developing golimumab, which was developed using Medarex's UltiMAb Human Antibody Development System.
Schering-Plough and Centocor
In August 2005, Schering-Plough announced that it exercised its right to develop and commercialize golimumab with Centocor (a unit of JNJ). Pursuant to the exercise, Schering-Plough receives exclusive worldwide marketing rights to golimumab, excluding the U.S., Japan, China (including Hong Kong), Taiwan, and Indonesia. The company has the right to market golimumab for 15 years after the first commercial sale in its territories. In exchange for its rights under this agreement, Schering-Plough made an upfront payment in the amount of $124 million to Centocor before a tax benefit of $6 million. Schering-Plough will share developmentcosts with Centocor.
In December 2007, Centocor and SGP revised their 1998...See full deal structure in Biomedtracker
Partners: Bristol-Myers Squibb Company Merck & Co., Inc. Mitsubishi Tanabe Pharma Corporation DRI Capital Inc.
Simponi (SQ) News
Pink Sheet Simponi FDA Reviewers
Pink Sheet Simponi Clinical Development
Pink Sheet FDA Approves Simponi For Ulcerative Colitis
Additional information available to subscribers only: